Eslicarbazepine acetate: a new promising antiepileptic agent

Jain, Sumit Kumar and Vasantharaju, SG and Muddukrishna, BS (2011) Eslicarbazepine acetate: a new promising antiepileptic agent. Elixir Pharmacy , 41. pp. 5736-5740.

[img] PDF
S._G._Vasantharaju__MAHE0006493.pdf - Published Version
Restricted to Registered users only

Download (104kB) | Request a copy


Eslicarbazepine acetate is a third generation, single enantiomer [(S)-(-)-10-acetoxy-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide] member of the commonly prescribed firstline antiepileptic drugs (AEDs), formerly known as BIA 2-093, is a novel central nervous system (CNS)-active compound with anticonvulsant activity. It is a prodrug which is activated to eslicarbazepine (S-licarbazepine), an active metabolite of oxcarbazepine. Eslicarbazepine acetate is used as an adjunctive therapy in adult patients with partial onset seizures. It behaves as a voltage-gated sodium channel (VGSC) blocker and is currently marketed for the treatment of epilepsy. Eslicarbazepine acetate shares with carbamazepine and oxcarbazepine the dibenzazepine nucleus bearing the 5-carboxamide substitute, but is structurally different at the 10,11-position. This molecular variation results in differences in metabolism, preventing the formation of toxic epoxide metabolites such as carbamazepine- 10,11 epoxide. This drug is considered as an adjunct to carbamazepine and oxcarbazepine.

Item Type: Article
Uncontrolled Keywords: Antiepileptic Drugs, Eslicarbazepine acetate, Excretion
Subjects: Pharmacy > MCOPS Manipal > Pharmaceutical Quality Assurance
Depositing User: KMC EPrints Administrator
Date Deposited: 21 Dec 2011 07:05
Last Modified: 21 Dec 2011 07:05

Actions (login required)

View Item View Item